Bartłomiej Matejko

Dr. Bartłomiej Matejko

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 August 2022 in Diabetes Care
Verified
Journal Article
Open access
PDF file
BMBartłomiej Matejko
Bartłomiej Matejko
AJAnna Juza
Anna Juza
BKBeata Kieć-Wilk
Beata Kieć-Wilk
KCKatarzyna Cyranka
Katarzyna Cyranka
SKSabina Krzyżowska
Sabina Krzyżowska
TKTomasz Klupa
Tomasz Klupa
OBJECTIVE: The aim of this study was to evaluate the outcomes of transitioning to the MiniMed 780G advanced hybrid closed-loop (AHCL) system in adult individuals with type 1 diabetes mellitus (T1DM) naive to continuous subcutaneous insulin infusion (CSII) and continuous glucose monitoring (CGM) technologies. RESEARCH DESIGN AND METHODS: This was a two-center, randomized, controlled, parallel-group trial with evaluation of individuals with T1DM aged 26–60 years managed with multiple daily injections (MDI) and self-monitoring of blood glucose (BGM) with HbA1c <10%. RESULTS: A total of 41 participants were recruited and randomized to either the AHCL (n = 20) or the MDI+BGM (n = 21) group, and 37 participants (mean ± SD age 40.3 ± 8.0 years, duration of diabetes 17.3 ± 12.1 years, BMI 25.1 ± 3.1 kg/m2, HbA1c 7.2 ± 1.0%) completed the study. Time spent with glucose levels in target range increased from 69.3 ± 12.3% at baseline to 85.0 ± 6.3% at 3 months in the AHCL group, while remaining unchanged in the control group (treatment effect 21.5% [95% CI 15.7, 27.3]; P < 0.001). The time with levels below range (<70 mg/dL) decreased from 8.7 ± 7.3% to 2.1 ± 1.7% in the AHCL group and remained unchanged in the MDI+BGM group (treatment effect −4.4% [95% CI −7.4, −2.1]; P < 0.001). Participants from the AHCL group also had significant improvements in HbA1c levels (treatment effect −0.6% [95% CI −0.9, −0.2]; P = 0.005) and in quality of life (QoL) in specific subscales compared with the MDI+BGM group. CONCLUSIONS: People with T1DM naive to CSII and CGM technologies initiating AHCL significantly and safely improved their glycemic control, as well as their QoL and psychological well-being.

12 January 2021 in Microorganisms
Verified
Journal Article
Open access
PDF file
SMSandra Mrozinska
Sandra Mrozinska
PKPrzemysław Kapusta
Przemysław Kapusta
Tomasz GosiewskiTomasz Gosiewski
Tomasz Gosiewski
ASAgnieszka Sroka-Oleksiak
Agnieszka Sroka-Oleksiak
ALAgnieszka H. Ludwig-Słomczyńska
Agnieszka H. Ludwig-Słomczyńska
TKTomasz Klupa
Tomasz Klupa
Recently, several studies explored associations between type 1 diabetes (T1DM) and microbiota. The aim of our study was to assess the colonic microbiota structure according to the metabolic control in T1DM patients treated with insulin pumps. We studied 89 T1DM patients (50.6% women) at the median age of 25 (IQR, 22–29) years. Pielou’s evenness (p = 0.02), and Shannon’s (p = 0.04) and Simpson’s diversity indexes (p = 0.01), were higher in patients with glycosylated hemoglobin (HbA1c) ≥ 53 mmol/mol (7%). There were no differences in beta diversity between groups. A linear discriminant analysis effect size (LEfSe) algorithm showed that one family (Ruminococcaceae) was enriched in patients with HbA1c < 53 mmol/mol, whereas one family (Streptococcaceae) and four species (Ruminococcus torques, unclassified species of Lactococcus, Eubacteroim dolichum, and Coprobacillus cateniformis) were enriched in patients with HbA1c ≥ 53 mmol/mol. We found that at class level, the following pathways according to Kyoto Encyclopedia of Genes and Genomes were enriched in patients with HbA1c < 53 mmol/mol: bacterial motility proteins, secretion system, bacterial secretion system, ribosome biogenesis, translation proteins, and lipid biosynthesis, whereas in patients with HbA1c ≥ 53 mmol/mol, the galactose metabolism, oxidative phosphorylation, phosphotransferase system, fructose, and mannose metabolism were enriched. Observed differences in alpha diversity, metabolic pathways, and associations between bacteria and HbA1c in colonic flora need further investigation.

24 January 2023 in JMIR Formative Research
Verified
Journal Article
Open access
KCKatarzyna Cyranka
Katarzyna Cyranka
BMBartłomiej Matejko
Bartłomiej Matejko
AJAnna Juza
Anna Juza
BKBeata Kieć-Wilk
Beata Kieć-Wilk
SKSabina Krzyżowska
Sabina Krzyżowska
TKTomasz Klupa
Tomasz Klupa
Background: While introducing new technologies and methods of treatment for type 1 diabetes mellitus (T1DM), it seems essential to monitor whether modern technologies in diabetes treatment may improve the psychological and emotional status of patients. Objective: This study aims to assess the baseline psychological parameters of patients with T1DM during investigation of the direct transition from multiple daily injections (MDI) and self-monitoring of blood glucose (SMBG) to the MiniMed 780G advanced hybrid closed-loop (AHCL) system and to evaluate changes in the psychological well-being and quality of life (QoL) after the transition in these individuals versus the control group. Methods: The trial was a 2-center, randomized controlled, parallel group study. In total, 41 patients with T1DM managed with MDI or SMBG were enrolled and randomized either to the AHCL or the MDI+SMBG group. Of these, 37 (90%) participants (mean age 40.3 years, SD 8.0 years; mean duration of diabetes 17.3, SD 12.1 years; mean hemoglobin A1c [HbA1c] 7.2%, SD 1.0%) completed the study (AHCL: n=20, 54%; MDI+SMBG: n=17, 46%). Psychological parameters (level of stress, coping mechanisms, level of anxiety, self-efficacy level, acceptance of illness, locus of control of illness, life satisfaction, QoL) were measured at baseline and at the end of the study using 10 psychological questionnaires. Results: At baseline, the general level of stress of the examined patients was higher than in the general healthy Polish population (P=.001), but coping strategies used in stressful situations were significantly more effective and the level of self-efficacy (P<.001) was much higher than in the general population. The patients in this study accepted their illness more than patients with diabetes from the general Polish population (P<.001), but they felt that their health does not depend on them compared to the general population (P<.001). The overall life satisfaction was similar to that of the general population (P=.161). After 3 months from transition, the AHCL group reported an increase in 4 scales of the QoL—feeling well (P=.042), working (P=.012), eating as I would like (P=.011), and doing normal things (P=.034)—in comparison to the control group, where no significant change occurred. The level of both state anxiety and trait anxiety decreased in the AHCL group: State-Trait Anxiety Inventory (STAI) X1 scores (P=.009), STAI X1 stens (P=.013), and STAI X2 scores (P=.022). The AHCL group became more emotion oriented in stressful situations (Coping Inventory for Stressful Situations [CISS] E; P=.043) and significantly less self-blaming after 3 months of the study (P=.020). Conclusions: The results indicate that the patients who decided to take part in the transition study were characterized by higher levels of stress than the general healthy population but had better coping strategies and self-efficacy. Furthermore, transitioning from MDI+SMBG treatment to the AHCL in patients naive to technology may significantly improve psychological well-being and QoL within 3 months. The rapidity of these changes suggests that they may be related to the significant improvement in glycemic outcomes but also significantly less burdened diabetes self-management. Trial Registration: ClinicalTrials.gov NCT04616391; https://clinicaltrials.gov/ct2/show/NCT04616391

24 January 2022 in International Journal of Endocrinology
Verified
Journal Article
Open access
PDF file
DUDamian Ucieklak
Damian Ucieklak
SMSandra Mrozinska
Sandra Mrozinska
AWAleksandra Wojnarska
Aleksandra Wojnarska
MMMaciej Malecki
Maciej Malecki
TKTomasz Klupa
Tomasz Klupa
BMBartłomiej Matejko
Bartłomiej Matejko
Background. Lipohypertrophy (LH) of subcutaneous tissue is an insulin-induced complication occurring in patients with diabetes. We aimed to define the prevalence of LH and identify its risk factors in type 1 diabetes (T1DM) patients treated with continuous subcutaneous insulin infusion (CSII). Materials and Methods. The study included 79 consecutive CSII-treated T1DM patients. The diagnose of LH was based on ultrasonography (US) as a reference method, physical examination was also performed. Clinical characteristics were available from the medical records. Results. The median age of patients was 28years (interquartile range [IQR], 2430.5) with a body mass index (BMI) of 24.5±3.5kg/m2, HbA1c 7.1 (IQR, 6.78.1), T1DM duration 15 (920) years, and CSII use duration of 8year (IQR, 511). LH was detected by US in 75 (94.9) patients. This value was much higher than this obtained by visual assessment (n=39, 49.4) or palpation (n=59, 74.7). In univariate analyses, the following risk factors for occurrence of 5 and more LH lesions were identified: the ratio of insulin dose to body mass exceeding 0.7IU/kg (OR, 3.69; 95 CI, 1.4310.01) and the total daily insulin dose (OR, 1.05; 95 CI, 1.021.09). A higher dose of insulin per kg remained a significant risk factor of LH amount in multivariate analysis. Conclusion. This selected T1DM cohort treated with CSII had a very high prevalence of LH. US assessment should be considered as a reference method for LH screening in T1DM patients. The identified risk factors for the number of LH lesions were related to insulin dosing.

2 May 2016 in Atherosclerosis
Verified
Journal Article
Closed access
PDF file
BKBeata Kiec-Wilk
Beata Kiec-Wilk
BMBartłomiej Matejko
Bartłomiej Matejko
URUrszula Razny
Urszula Razny
MSMagdalena Stankiewicz
Magdalena Stankiewicz
JSJan Skupien
Jan Skupien
MMMaciej Malecki
Maciej Malecki

31 July 2023 in Diabetes Technology & Therapeutics
Verified
Journal Article
Closed access
BMBartłomiej Matejko
Bartłomiej Matejko
AJAnna Juza
Anna Juza
BKBeata Kieć-Wilk
Beata Kieć-Wilk
KCKatarzyna Cyranka
Katarzyna Cyranka
SKSabina Krzyżowska
Sabina Krzyżowska
TKTomasz Klupa
Tomasz Klupa
The aim of this study was to observe the 1-year clinical outcomes of people with type 1 diabetes who switched from multiple daily injection + blood glucose meter to an advanced hybrid closed-loop (AHCL) system (Medtronic MiniMed™ 780G system [MM 780G]). In addition, the effect of changing at month 6 to a calibration-free sensor (Guardian™ 4 Sensor [G4S]) was evaluated. Eighteen participants (10 men, age 40.9 ± 7.6 years) completed 1 year of MM 780G use. Time in range (TIR; 70–180 mg/dL) remained stable and ranged from 83.2% in month 9 to 84.8% in month 3. There was no difference between TIR at 3 months before switching versus 3 months after switching to G4S ( P = 0.614). AHCL system in adults significantly improves glycemic outcomes. This improved glycemic control was maintained over the 12 months. Switching to a calibration-free sensor (G4S) did not affect outcomes but required less patient involvement.